Across
- 3. Biologic therapy approved by the FDA in 2025 for moderate to severe hidradenitis suppurativa.
- 5. Rare benign sweat gland tumor with eccrine or apocrine origin.
- 7. First-in-class topical therapy targeting hormonal influence in acne pathogenesis
- 8. A novel mutation in which gene has been linked to a combined phenotype of Dowling-Degos disease and hidradenitis suppurativa, suggesting a pivotal role in Notch signaling within follicular structures​
- 11. Common topical agent exacerbating acne.
- 12. Acne variant with systemic symptoms and ulcerations.
Down
- 1. Neurotransmitter stimulating eccrine sweat glands.
- 2. Prickly heat rash caused by sweat duct obstruction.
- 4. AMP family contributing to innate immunity and dysregulated in acne
- 6. Malodorous sweat disorder linked to bacterial metabolism.
- 9. Primary site of Fox-Fordyce disease involvement.
- 10. Key inflammatory mediator driving HS progression.